Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Nektar Therapeutics
0UNLCurrent price
1.24 USD
-0.05 USD (-3.88%)
Last closed
1.31 USD
Company
www.nektar.com
ISIN
US6402681083
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
241 143 488 USD
Yield for 12 month
+84.06 %
1Y
3Y
5Y
10Y
15Y
0UNL
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. Address: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.3 USDP/E ratio
–Dividend Yield
–Current Year
+90 122 000 USD
Last Year
+92 055 000 USD
Current Quarter
+23 489 000 USD
Last Quarter
+21 639 000 USD
Current Year
+53 478 000 USD
Last Year
+70 420 000 USD
Current Quarter
+13 749 000 USD
Last Quarter
+13 105 000 USD
Key Figures 0UNL
1 year
3 years
5 years
10 years
EBITDA
-128 688 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.16 %
PEG Ratio
3.22
Return On Equity TTM
-128.02 %
Wall Street Target Price
1.3 USD
Revenue TTM
93 157 000 USD
Book Value
0.43 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
14.6 %
Dividend Yield
–
Gross Profit TTM
70 420 000 USD
Earnings per share
-0.9 USD
Diluted Eps TTM
-0.9 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-190.09 %
Dividend Analytics 0UNL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0UNL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
2:1
Payout Ratio
–
Last Split Date
23.08.2000
Dividend Date
–
Stock Valuation 0UNL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.8803
Price Sales TTM
2.5886
Enterprise Value EBITDA
-6.4992
Price Book MRQ
3.0261
Financials 0UNL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0UNL
For 52 weeks
0.41 USD
1.93 USD
50 Day MA
1.28 USD
Shares Short Prior Month
8 473 759
200 Day MA
1.05 USD
Short Ratio
8.83
Shares Short
8 237 686
Short Percent
5.72 %
BeatStart